Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50242-0933-01 50242-0933 Atezolizumab and hyaluronidase-tqjs Tecentriq Hybreza 1875.0 mg/15mL, 30000.0 U/15mL Immunotherapy Checkpoint Inhibitor PD-L1 Subcutaneous Sep 12, 2024 In Use
00003-3772-11 00003-3772 Nivolumab Opdivo 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 22, 2014 In Use
00003-3756-14 00003-3756 nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Aug 30, 2021 In Use
00173-0898-03 00173-0898 dostarlimab Jemperli 50.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Apr 22, 2021 In Use
00003-2328-22 00003-2328 Ipilimumab Yervoy 5.0 mg/mL Immunotherapy Checkpoint Inhibitor CTLA-4 Intravenous Mar 25, 2011 In Use
50242-0933-86 50242-0933 Atezolizumab and hyaluronidase-tqjs Tecentriq Hybreza 1875.0 mg/15mL, 30000.0 U/15mL Immunotherapy Checkpoint Inhibitor PD-L1 Subcutaneous Sep 12, 2024 In Use
50881-0006-03 50881-0006 Retifanlimab-dlwr ZYNYZ 25.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Mar 22, 2023 In Use
00006-3026-02 00006-3026 Pembrolizumab Keytruda 25.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Jan 15, 2015 In Use
00003-7125-11 00003-7125 nivolumab and relatlimab-rmbw OPDUALAG 12.0 mg/mL, 4.0 mg/mL Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 Intravenous Mar 18, 2022 In Use
73153-0900-01 73153-0900 Lisocabtagene maraleucel BREYANZI Immunotherapy CAR-T CD19 Feb 5, 2021 In Use
00078-0958-19 00078-0958 tisagenlecleucel KYMRIAH 60000000.0 1/1 Immunotherapy CAR-T CD19 Intravenous May 1, 2018 In Use
00078-0846-19 00078-0846 Tisagenlecleucel Kymriah 2000000.0 1/1 Immunotherapy CAR-T CD19 Intravenous Aug 30, 2017 In Use
71287-0219-02 71287-0219 brexucabtagene autoleucel TECARTUS 2000000.0 1/68mL Immunotherapy CAR-T CD19 Intravenous Jul 24, 2020 In Use
71287-0119-02 71287-0119 Axicabtagene ciloleucel Yescarta 2000000.0 1/68mL Immunotherapy CAR-T CD19 Intravenous Oct 18, 2017 In Use
71287-0220-02 71287-0220 brexucabtagene autoleucel TECARTUS 1000000.0 1/68mL Immunotherapy CAR-T CD19 Intravenous Oct 1, 2021 In Use
59572-0515-01 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Mar 26, 2021 In Use
59572-0515-03 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Mar 26, 2021 In Use
59572-0515-02 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Mar 26, 2021 In Use
57894-0111-02 57894-0111 ciltacabtagene autoleucel CARVYKTI 100000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Feb 28, 2022 In Use
57894-0111-01 57894-0111 ciltacabtagene autoleucel CARVYKTI 100000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Feb 28, 2022 In Use
70255-0025-05 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral Aug 3, 2020 In Use
70255-0025-06 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral Aug 3, 2020 In Use
70255-0025-03 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral Jun 27, 2018 In Use
70255-0025-01 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral Jun 27, 2018 In Use
70255-0020-01 70255-0020 Encorafenib BRAFTOVI 50.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral Jun 27, 2018 Mar 13, 2019 In Use

Found 11120 results — Export these results